A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.
Dijkman
G A
GA
Department of Urology, St. Ignatius Hospital, Breda, The Netherlands.
Debruyne
F M
FM
Fernandez del Moral
P
P
Plasman
J W
JW
Hoefakker
J W
JW
Idema
J G
JG
Sykes
M
M
D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D017273:Goserelin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D017273:Goserelin